Use of the SpiderMass for in Vivo Analysis of the Skin in Five Chronic Inflammatory Dermatosis

Using the SpiderMass(TM) for in Vivo and Real Time Mass Spectrometry Analysis of Subject's Epidermis Suffering From Chronic Inflammatory Dermatosis Compared to Control Groups

The physiological states of the skin are characterized by a certain homeostasis linked to the balance of the metabolic pathways. When these pathways are deregulated, the proteic, lipidic and metabolic is affected. It is thus possible to follow a change in the state of the skin by looking at change in the associated molecular profile.

The PRISM laboratory (INSERM U1192) in Lille has developed an innovative system laser called SpiderMass composed of 4 parts:

1. A laser used for the micro-sampling of material in vivo,
2. A transport transfer line of the ablated particles,
3. A mass spectrometer that analyzes them in real time and generates the molecular profiles of the epidermis,
4. A data analysis procedure.

The SpiderMass(TM) is of great interest for the study of the skin because it allows non-invasive vivo characterization, and therefore without biopsy or sample preparation. In addition, it will complement techniques already used in the research center such as FTIR spectroscopy. Indeed, in acne studies the FTIR allows to obtain only the Fatty Acid Triglycerid ratio while the SpiderMass permits to detail these lipid classes by each observed molecule on the surface of the skin and follow their evolution.

Study Overview

• Status: Unknown
• Conditions: Healthy; Rosacea; Seborrheic Dermatitis; Atopic Dermatitis; Psoriasis Vulgaris; Acne
• Intervention / Treatment: Other: in-vivo mesure; Other: Scotch; Other: Lipid index; Other: Absorbant paper; Other: Hydratation Index; Other: TransEpidermal Water Loss

• Study Type: Interventional
• Enrollment (Anticipated): 220
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Gwendal JOSSE, Mr; Phone Number: +33562488515; Email: gwendal.josse@pierre-fabre.com

Study Locations

• France
  • Toulouse, France, 31400
    • Recruiting
    • Centre de Recherche sur la Peau
    • Contact: Thérèse Dr NOCERA; Phone Number: +33 (0)5 62 48 85 93; Email: therese.nocera@pierre-fabre.com
    • Principal Investigator: Thérèse NOCERA, Dr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

--> INCLUSION CRITERIA

CRITERIA RELATED TO THE POPULATION:

• Male or female subject having signed a written informed consent for his/her participation to the study
• Subject with a phototype II to IV according to the Fitzpatrick scale
• Subject affiliated to a social security system or health insurance, or is a beneficiary
• For woman of childbearing potential use of an effective method of contraception, as assessed by the investigator for at least 4 weeks before inclusion in the study

For acne of the face subgroup and its associated control: Male or female, 18 to 30 years old included

For atopic dermatitis of the upper limb subgroup and its associated control: Male or female, 20 to 50 years old included

For vulgar plaque psoriasis subgroup and its associated control: Male or female, 20 to 55 years old included

For telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: Male or female, 30 to 55 years old included

For seborrheic dermatitis of scalp subgroup and its associated control: Male or female, 20 to 45 years old included

CRITERIA RELATED TO DERMATOSIS:

For subjects of the acne of the face subgroup :

-Subjects with mild to severe acne on the face with a GEA (Global Acne Evaluation) score of 2 to 4 on a rating scale ranging from 0 (no injury) to 5 (very severe)

• Subject presenting on the face, at least one zone:

  • Lesional in immediate border of a papule
  • Peri-lesional near inflammatory lesions (papule, about 1 cm)
• Subject presenting on the inner side of the forearm a reference zone without lesion

For subjects in the atopic dermatitis subgroup of upper limbs:

• Subject with atopic dermatitis on the upper limbs, mild to moderate with SCORAD (SCORing Atopic Dermatitis) between 15 and 40 included with:

  •A dryness score ≥ 2 on a scale ranging from 0 (absent) to 3 (severe)

• Subject having at least one inflammatory flare of atopic dermatitis on the upper limbs in the 2 years before the day of inclusion

• Subject presenting on the upper limb (hand excluded) at least one zone:

  •Lesional defined by the signs of target SCORAD between 3 and 12:

  • Erythema from 1 to 3

  • Dryness ≥2

  • Oedema / papule from 0 to 3

  • Lesions oozing or crusting 0
  • Excoriation of 0
  • Lichenification from 0 to 3 On a scale ranging from 0 (absent) to 3 (severe)
  • Peri-lesional near the lesion zone (about 1cm)
• Subject presenting on the inner side of the forearm a reference zone without lesion

For vulgar plaque psoriasis subgroup

• Subject with mild to moderate erythematous-squamous plaque psoriasis whose IGA (Investigator Global Assessment) score is between 2 and 3, on a rating scale ranging from 0 (clear) to 5 (very severe)

• Subject with on the upper limb (hand excluded) or lower limb at least one zone:

  • Lesional:
  • Without fissure and without crust
  • With erythema score ≥ 1 on a scale ranging from 0 (absent) to 3 (severe)
  • With desquamation score between 1 (mild) and 2 (moderate) on a scale ranging from 0 (absent) to 3 (severe)
  • With an oedema score of 0 (absent) on a scale ranging from 0 (absent) to 3 (severe)
  • Peri-lesional:
  • Without fissure and without crust
  • Near the lesion zone (about 1 cm)
  • Subject presenting on the inner side of the forearm a reference zone without lesion

For telangiectasic erythrocouperosis papule of the face (rosacea) subgroup

- Subject with telangiectasic erythrocouperosis and papule of the face mild to moderate with an IGA score between 2 and 3 on a rating scale ranging from 0 (absent) to 4 (severe)

• Subject presenting on the face at least one zone:

  • Lesional: immediate border of the papule with a persistent erythema score ≥ 1 on a rating scale ranging from 0 (absent) to 3 (severe)

  • Peri-lesional:

  • Near inflammatory lesions (papule, about 1 cm)

  • Ranging of at least 1 point less in the erythema score compared to the lesion zone

• Subject presenting on the inner side of the forearm a reference zone without lesion

For seborrheic dermatitis of scalp subgroup :

• Subject with mild to moderate seborrheic dermatitis with an IGA score between 2 and 3 on a rating scale ranging from 0 (absent) to 4 (severe)

• Subject presenting on the scalp at least one zone:

  • Lesional:
  • with erythema score ≥ 1 on a scale of 0 (absent) to 3 (severe)
  • with clinically visible scales
  • Peri-lesional:Near the lesion zone (about 1 cm)

• Subject presenting on the inner side of the forearm a reference zone without lesion

  • NON INCLUSION CRITERIA

CRITERIA RELATED TO THE POPULATION:

• For woman of childbearing potential: pregnant or breastfeeding
• Subject unable to understand the information given including study procedures (for linguistic or psychiatric reasons) and to give his/her consent in writing
• Subject who, in the judgement of the investigator, is not likely to be compliant with study-related constraints and requirements
• Subject who has forfeited his/her freedom by administrative or legal award or is under guardianship
• Subject who is in a position likely to represent a conflict of interest and/or is a family member of any people involved in the conduct of the study (secretary, nurse, technician…) of the investigational site
• Subject who is currently participating, who plans to participate or who has participated in another clinical study liable to interfere with the study assessments according to the investigator's assessment

CRITERIA RELATED TO DERMATOSIS AND CUTANEOUS CONDITION:

• Subject with premature cutaneous aging linked to a genetic disease
• Subject with solar erythema in at least one zone under study
• Subject with a tattoo, scar or other dermatological sign on at least one study zone that may interfere with the study according to the investigator's assessment
• Subject with autoimmune disease
• Subject with any type of complication on at least one study area (excoriation type, primary, viral, fungal or parasitic bacterial infection, etc.) according to the investigator's assessment

Criteria for control subgroups:

- Subject with a dermatosis or any type of lesion on the zone corresponding to the lesional, peri-lesional zone or reference zone of the associated subgroup dermatosis likely to interfere with the study according to the investigator's assessment

Criteria for chronic inflammatory dermatitis:

For subjects of the acne of the face subgroup:

- Subject with another dermatosis (chronic / acute, inflammatory, infectious, immune) on the face that could interfere with the study according to the investigator's assessment

For subjects in the atopic dermatitis subgroup of upper limbs:

- Subject with another dermatosis (chronic / acute, inflammatory, infectious, immune) on the upper limb (s) to the study likely to interfere with the study according to the investigator's assessment

For vulgar plaque psoriasis subgroup

• Subject with an isolated palmo-plantar form of psoriasis
• Subject with an isolated form of cutaneous psoriasis other than in plaque (in gout, pustular, erythrodermic or inverted elbow creases (psoriasis of the mucous membranes))
• Subject with another dermatosis (chronic / acute, inflammatory, infectious, immune) on the upper limb (s) and/or lower limb(s) to the study likely to interfere with the study according to the investigator's assessment

For telangiectasic erythrocouperosis papule of the face (rosacea) subgroup

- Subject with another dermatosis (chronic / acute, inflammatory, infectious, immune) on the face that could interfere with the study according to the investigator's assessment

For seborrheic dermatitis of scalp subgroup :

• Seborrheic dermatitis under medical treatment
• Subject with another dermatosis (chronic / acute, inflammatory, infectious, immune) on the scalp likely to interfere with the study according to the investigator's assessment (in particular contact eczema or alopecia)

CRITERIA RELATED TO TREATMENTS AND PRODUCTS

For all subjects :

• Oral intake of isotretinoin or acitretin (oral vit-A and derivatives) within the 6 months prior to the inclusion visit or the day of the visit
• Local retinoid treatment on at least one study zone, which may interfere with the results of the study according to the investigator's assessment within the month preceding the inclusion visit or the day of the visit
• Phototherapy treatment in at least one study zone within 4 weeks prior to the inclusion visit or the day of the visit
• Topical or oral treatment established or modified during the previous weeks or to be established or modified during the study, which may interfere with the results of the study according to the investigator's assessment ( for example modifying the cutaneous characteristics: treatment inducing pigmentation), keratolysis, ...)
• Anti-inflammatory treatment (steroidal or nonsteroidal) taken daily and repeatedly for more than 5 consecutive days during the week preceding the inclusion visit
• Application of any topical vitamin D-derived treatment on at least one study zone within 3 weeks prior to the inclusion visit or the day of the visit
• Application of dermocorticoid topical or immunomodulatory topical treatments (tacrolimus), antifungals, local antibiotics on at least one study zone in the 3 weeks prior to the inclusion visit or the day of the visit
• Application of water, product or topical treatment on at least one zone under study after the last wash the day before the visit
• Application of water, topical product or make-up on at least one zone the day of the inclusion visit

For seborrheic dermatitis of scalp subgroup and its associated control :

• Use on the scalp of any product that can be active on squamous conditions, rinsed or posed (anti-dandruff, anti-fungal shampoo, vinegar rinse, essential oils ...) within 2 weeks prior to the inclusion visit or the day of the visit
• Any technique to change the color or condition of the hair (coloring, discoloration, permanent, smoothing / straightening, ..) performed within 2 weeks prior to the inclusion visit or the day of the visit
• Washing of the scalp done within 2 days before the inclusion visit or the day of the visit

Study Plan

How is the study designed?

Design Details

• Primary Purpose: BASIC_SCIENCE
• Allocation: NON_RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
OTHER: Control subject group; Divided in 5 subgroups : A': associated to acne of the face subgroup; B' : associated to atopic dermatitis of the upper limb subgroup; C' : associated to vulgar plaque psoriasis subgroup; D' : associated to telangiectasic erythrocouperosis papule of the face (rosacea) subgroup; E' : associated to seborrheic dermatitis of scalp subgroup	Other: in-vivo mesure; for acne of the face subgroup and its associated control : face and inner side of the forearm; for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm; for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm; for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm; for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm; Other Names: SpiderMass mesure; Other: Scotch; for acne of the face subgroup and its associated control : face and inner side of the forearm; for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm; for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm; for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm; for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm; Other: Lipid index; for acne of the face subgroup and its associated control : face; for seborrheic dermatitis of scalp subgroup and its associated control: scalp; for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face; Other: Absorbant paper; for acne of the face subgroup and its associated control : face; for seborrheic dermatitis of scalp subgroup and its associated control: scalp; for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: forehead; Other: Hydratation Index; -for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded); Other: TransEpidermal Water Loss; -for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)
OTHER: Subject group with dermatitis; Divided in 5 subgroups : A : acne of the face subgroup; B : Atopic dermatitis of the upper limb subgroup; C : Vulgar plaque psoriasis subgroup; D : Telangiectasic erythrocouperosis papule of the face (rosacea) subgroup; E : Seborrheic dermatitis of scalp subgroup	Other: in-vivo mesure; for acne of the face subgroup and its associated control : face and inner side of the forearm; for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm; for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm; for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm; for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm; Other Names: SpiderMass mesure; Other: Scotch; for acne of the face subgroup and its associated control : face and inner side of the forearm; for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded) and inner side of the forearm; for vulgar plaque psoriasis subgroup and its associated control: upper limb (hand excluded) or lower limb and inner side of the forearm; for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face and inner side of the forearm; for seborrheic dermatitis of scalp subgroup and its associated control: scalp and inner side of the forearm; Other: Lipid index; for acne of the face subgroup and its associated control : face; for seborrheic dermatitis of scalp subgroup and its associated control: scalp; for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: face; Other: Absorbant paper; for acne of the face subgroup and its associated control : face; for seborrheic dermatitis of scalp subgroup and its associated control: scalp; for telangiectasic erythrocouperosis papule of the face (rosacea) subgroup and its associated control: forehead; Other: Hydratation Index; -for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded); Other: TransEpidermal Water Loss; -for atopic dermatitis of the upper limb subgroup and its associated control: upper limb (hand excluded)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Signals and molecular profiles (including lipid) of the epidermis	Defined by characteristic peak mass intensities - SpiderMass	baseline
Molecular profiles (including lipid) of the epidermis according to sampling method and the measurements of the signals obtained method	sampling method - absorbant paper, in vivo and / or by scotch; measurements of the signals obtained -in vivo or FTIR	baseline
Cutaneous hydratation for atopic dermatitis subgroup and its associated control	By hydratation index - Corneometer	baseline
State of the cutaneous barrier for atopic dermatitis and corresponding control volunteers	Rate of the Trans Epithelial Water Loss (TEWL) by arbitrary units with an Aquaflux system (Biox Systems Ltd, London. UK)	baseline
Global lipid quantity measured on face acnea, scalp seborrheic dermatitis, face rosacea (papulotelangiectasic stage of erythrocouperosis) and corresponding control volunteers	Global sebum level measurement expressed in arbitrary index with a Sebumeter SM815 system (Courage+Khazaka electronic GmbH, Köln. Germany)	baseline
Skin state evaluation on the lesional and perilesional areas	Illustrative descriptions of the skin state with photographs, taken by an iPhone 6S (Apple, Cupertino. Califronia, USA) dedicated to the study	baseline
Impact of several factors (dermatosis, area, gender, age) on the molecular profiles of the epidermis	Characteristic peak mass intensities - SpiderMass	baseline

Collaborators and Investigators

• Sponsor: Pierre Fabre Dermo Cosmetique
• Investigators: Principal Investigator: Thérèse NOCERA, Mrs, Centre de Recherche sur la Peau

Study record dates

Study Major Dates

• Study Start (ACTUAL): December 13, 2019
• Primary Completion (ANTICIPATED): September 15, 2021
• Study Completion (ANTICIPATED): September 15, 2021

Study Registration Dates

• First Submitted: June 5, 2020
• First Submitted That Met QC Criteria: July 10, 2020
• First Posted (ACTUAL): July 15, 2020

Study Record Updates

• Last Update Posted (ACTUAL): March 18, 2021
• Last Update Submitted That Met QC Criteria: March 17, 2021
• Last Verified: July 1, 2020

More Information

Terms related to this study

• Keywords: Rosacea; Psoriasis Vulgaris; seborrheic dermatitis; dermatitis; Laser; Transepidermal water loss; acne of the face; Atopic Dermatitis of the upper limb; SpiderMass; Lipid Index; Hydratation index; Scotch sampling; Absorbant paper
• Additional Relevant MeSH Terms: Immune System Diseases; Hypersensitivity, Immediate; Genetic Diseases, Inborn; Skin Diseases, Genetic; Skin Diseases, Papulosquamous; Hypersensitivity; Skin Diseases, Eczematous; Sebaceous Gland Diseases; Psoriasis; Dermatitis; Eczema; Rosacea; Dermatitis, Seborrheic; Skin Diseases; Dermatitis, Atopic
• Other Study ID Numbers: SMPATHO01; 2019-A02105-52 (OTHER: ID-RCB)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No